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Mammalian SWI/SNF chromatin-remodeling complexes utilize either BRG1 or Brm as alternative 
catalytic subunits to alter the position of nucleosomes and regulate gene expression. Genetic 
studies have demonstrated that SWI/SNF complexes are required during cardiac development and 
also protect against cardiovascular disease and cancer. However, Brm constitutive null mutants do 
not exhibit a cardiomyocyte phenotype and inducible Brg1 conditional mutations in 
cardiomyocyte do not demonstrate differences until stressed with transverse aortic constriction, 
where they exhibit a reduction in cardiac hypertrophy. We recently demonstrated the overlapping 
functions of Brm and Brg1 in vascular endothelial cells and sought here to test if this overlapping 
function occurred in cardiomyocytes. Brg1/Brm double mutants died within 21 days of severe 
cardiac dysfunction associated with glycogen accumulation and mitochondrial defects based on 
histological and ultrastructural analyses. To determine the underlying defects, we performed 
nontargeted metabolomics analysis of cardiac tissue by GC/MS from a line of Brg1/Brm double-
mutant mice, which lack both Brg1 and Brm in cardiomyocytes in an inducible manner, and two 
groups of controls. Metabolites contributing most significantly to the differences between 
Brg1/Brm double-mutant and control-group hearts were then determined using the variable 
importance in projection analysis. Increased cardiac linoleic acid and oleic acid suggest alterations 
in fatty acid utilization or intake are perturbed in Brg1/Brm double mutants. Conversely, decreased 
glucose-6-phosphate, fructose-6-phosphate, and myoinositol suggest that glycolysis and glycogen 
formation are impaired. These novel metabolomics findings provide insight into SWI/SNF-
regulated metabolic pathways and will guide mechanistic studies evaluating the role of SWI/SNF 
complexes in homeostasis and cardiovascular disease prevention.
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1 Introduction
Mammalian SWI/SNF (switching defective/sucrose non-fermenting) complexes are 
comprised of 9–12 subunits including either BRG1 (brahma-related gene 1, also known as 
SMARCA4) or BRM (brahma, also known as SMARCA2) as alternative catalytic subunits 
with DNA-dependent ATPase activity (Wu et al. 2009). These chromatin-remodeling 
complexes are recruited by pioneer transcription factors to the promoters of numerous target 
genes, where they slide or evict nucleosomes in an ATP-dependent manner to either activate 
or suppress RNA Polymerase II occupancy and transcription. In addition to BRG1 or BRM, 
SWI/SNF complexes contain 8–11 additional subunits called BAFs (BRG1/BRM associated 
factors with a number referring to the protein molecular mass) that contribute to chromatin 
remodeling. Due to the combinatorial assembly of different BAFs, there are potentially 
many distinct SWI/SNF complexes that vary in subunit composition and function (Wu et al. 
2009).
SWI/SNF complexes play an important role in cardiovascular development (Bevilacqua et 
al. 2013; Chang and Bruneau 2012). In humans, mutations in several genes encoding 
SWI/SNF subunits including BRG1 and BRM result in congenital syndromes that exhibit 
highly penetrant cardiac defects (Kosho et al. 2013a, b; Ronan et al. 2013; Santen et al. 
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2012; Tsurusaki et al. 2012; Van Houdt et al. 2012). Inmouse models, Baf250a, Baf180, and 
Baf60c constitutive null mutants exhibit a variety of cardiac defects including abnormal 
looping, hypoplastic ventricles, shortened outflow tracts, and septal defects that result in 
embryonic lethality (Lei et al. 2012; Lickert et al. 2004; Wang et al. 2004). Although Brg1 
constitutive nullmutants die prior to organogenesis (Bultman et al. 2000), conditional null 
mutations of Brg1 in the developing endocardium, myocardium, or myocardial progenitor 
cells of the secondary heart field result in a variety of defects including hypoplastic 
ventricles, thin myocardium, shortened outflow tract, lack of septum, and hypotrebeculation 
that also culminate in embryonic lethality (Hang et al. 2010; Stankunas et al. 2008; Takeuchi 
et al. 2011). An essential role for BRG1 in cardiomyocyte development is consistent with it 
physically interacting with the cardiogenic transcription factors TBX5, GATA4, and 
NKX2.5, and the ability of BAF60c, TBX5, and GATA4 to differentiate non-cardiac 
mesoderm into beating cardiomyocytes (Hang et al. 2010; Kadoch et al. 2013; Takeuchi and 
Bruneau 2009). While Brg1 is essential for cardiomyocyte development, it is dispensable for 
cardiomyocyte viability in the adult animal (Hang et al. 2010). However, an inducible 
conditional mutation of Brg1 in adult cardiomyocytes did result in decreased hypertrophy 
following transverse aortic constriction to pressure overload the heart (Hang et al. 2010). In 
contrast, Brm constitutive null mutants are viable and do not exhibit a discernable 
cardiomyocyte phenotype compared to sibling wild-type controls (Han et al. 2011; Reyes et 
al. 1998). The combined role of Brg1 and Brm in the adult cardiomyocyte has not previously 
been described.
The redundancy of Brg1 and Brm in vascular endothelial cells (VECs) within the adult heart 
has recently been reported. Brg1 is required by VECs during embryonic development, 
whereas Brm is dispensable (Curtis et al. 2012; Griffin et al. 2008; Griffin et al. 2011; 
Nelson et al. 2005). Furthermore, the Brg1 mutant phenotype of developing VECs is not 
exacerbated by Brm deficiency (Griffin et al. 2008). However, an inducible conditional 
mutation of Brg1 in VECs from adult mice did not result in an observable phenotype (Willis 
et al. 2012). The lack of an adult phenotype was found to be due to the redundancy of Brg1 
and Brm in the adult VECs within the heart, as double mutants died within 30 days of 
inducing the Brg1 deletion (Willis et al. 2012). Absence of Brg1 and Brm resulted in VEC 
apoptosis, vascular leakage, intra-cardiac dissection, and secondary cardiomyocyte cell 
death due to ischemia (Willis et al. 2012).
Considering that Brg1 and Brm are functionally redundant in adult VECs, we hypothesized 
that they may also have redundant functions in adult cardiomyocytes. To test this 
hypothesis, we analyzed Brg1/Brm double mutants where Brg1 could be mutated 
exclusively in cardiomyocytes in an inducible manner. Indeed, double mutants were not 
viable and their hearts exhibited signs of metabolic dysfunction. Therefore, we sought to 
characterize metabolomic changes in double mutants compared to controls. Recent advances 
in technology have afforded a more comprehensive analysis of a tissue’s metabolome. Both 
targeted and non-targeted mass spectrometry based approaches have become common, with 
non-targeted methods being particularly valuable to explore phenotypes that involve many 
metabolites in a relatively unbiased manner (Bain et al. 2009). Non-targeted technologies 
have been used to characterize genetic diseases that result in altered metabolism of 
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carbohydrates, lipids, and amino acids (Frazier et al. 2006). The present studies demonstrate 
that BRG1 and BRM are required for metabolic homeostasis. Brg1/Brm double-mutant 
hearts exhibited altered metabolism of fatty acids (e.g. increased cardiac oleic and linoleic 
acids), glucose (e.g. decreased glucose-6-P, fructose-6-P, myoinositol), and amino acids. 
Both fatty acid and glucose substrate utilization has been shown to be a critical regulator of 
the heart’s resiliency in the face of cardiac disease, with resulting fatty acid and glucose 
toxicity identified when there is an imbalance matched to the stressor (Carley et al. 2014; 
Doenst et al. 2013; Kolwicz et al. 2013). These studies demonstrate the critical role that 
BRG1 and BRM play in regulating fatty acid and glucose metabolism in the intact adult 
cardiomyocyte, likely by supporting the activity of multiple nuclear receptors implicated in 
regulating fatty acid and glucose utilization in the heart (e.g. PPAR, PGC1α) (Debril et al. 
2004; Gatfield et al. 2009; Li et al. 2008; Wang et al. 1996).
2 Materials and Methods
2.1 Mouse Lines
All mouse experiments were approved by the Institutional Animal Care and Use 
Committees (IACUC) review board at the University of North Carolina at Chapel Hill and 
were performed in accordance with federal guidelines. The αMHC-Cre-ERT mice [also 
known as B6.Cg-Tg(Myh6-cre/Esr1)1JmkJ or αMHC-MerCreMer] were obtained from The 
Jackson Laboratory (#005657, Bar Harbor, ME) and genotyped as previously described 
(Sohal et al. 2001). The Brg1 conditional mutant mouse line and Brm constitutive mutant 
mouse line have been described previously (Bultman et al. 2000; Reyes et al. 1998; Sumi-
Ichinose et al. 1997). Genotyping of the Brg1 floxed and Δfloxed alleles and the Brm 
mutation were genotyped by PCR as previously described (Bultman et al. 2000; Reyes et al. 
1998; Sumi-Ichinose et al. 1997).
2.2 Tamoxifen Induction of Brg1 Mutation
To induce the Brg1 conditional mutation in adult cardiomyocytes, 3–6 month old male and 
female mice were provided rodent chow containing tamoxifen (Sigma-Aldrich #T5648, St. 
Louis, MO) over a 7-day period. The route of delivery and dose were selected to minimize a 
previously described artifact caused by high doses of tamoxifen in the presence of the 
αMHC-Cre-ERT transgene (Koitabashi et al. 2009). Briefly, 500 mg of tamoxifen was 
mixed with 1 kg of ground-up rodent chow and then mixed with water, kneaded into pellets, 
and dried in a hood. Provided to mice ad libitum, the dose was estimated to be 80 mg/kg/
day. After the 7-day treatment period, the tamoxifen-fortified chow was removed and 
replaced with the same chow lacking tamoxifen.
2.3 Echocardiography
Conscious cardiac transthoracic echocardiography was performed on mice at the indicated 
time points using a VisualSonics Vevo 2100 ultrasound biomicroscopy system 
(VisualSonics, Inc., Toronto, Ontario, Canada) as previously described (Files et al. 2012; 
Oakley et al. 2013; Willis et al. 2009a,b). Two-dimensional M-mode echocardiography was 
performed in the parasternal long-axis view at the level of the papillary muscle on loosely 
restrained mice. Anterior and posterior wall thickness was measured as distance from 
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epicardial to endocardial leading edges. Left ventricular internal diameters were also 
measured. Left ventricular systolic function was assessed by ejection fraction (LV EF% = 
[(LV Vol; d-LV Vol; s/LV Vol; d) × 100] and fractional shortening (%FS = [(LVEDD − 
LVESD)/LVEDD] × 100). Investigators were blinded to mouse genotype from collection 
through waveform measurements. Each measurement represents the average of three cardiac 
cycles from each mouse.
2.4 Histopathological and Ultrastructural Analyses
Histology was performed by fixing heart tissues in 4 % paraformaldehyde, embedding in 
paraffin, cutting 5-μm sections, and staining sections with hematoxylin and eosin (H&E) 
according to standard procedures. For transmission electron microscopy (TEM), heart 
tissues were fixed in 2 % paraformaldehyde and 2.5 % glutaraldehyde in 0.15 M sodium 
phosphate buffer (pH 7.4) overnight and then post-fixed with 1 % osmium tetroxide in 0.15 
sodium phosphate buffer. Samples were dehydrated with increasing concentrations of 
ethanol, infiltrated and embedded in Polybed 812 epoxy resin (Polysciences, Warrington, 
PA), and 70-nm ultrathin sections were cut with a diamond knife. Sections were mounted on 
200-mesh copper grids and staining with 4 % aqueous uranyl acetate and Reynold’s lead 
citrate. Sections were observed with a LEO EM910 transmission electron microscope 
operating at 80 kV (LEO Electron Microscopy, Thornwood, NY) and photographed with a 
Gatan-Orius SC1000 CCD Digital Camera and Digital Micrograph 3.11.0 (Gatan, 
Pleasanton, CA).
2.5 RT-qPCR Analysis
RNA from double-mutant and control hearts was prepared using Trizol reagent (Life 
Technologies) and reverse transcribed using random hexamers and SuperScript II RT (Life 
Technologies) according to standard procedures. Pfk-fb1 was amplified using the following 
primers (5′GAGTG CAAGACCACGTTCAA3′ and 5′GGAGCTGATGCTTT GAGACC3′ 
at 300 nM final concentration for each) and Power SYBR Green Master Mix (Life 
Technologies) under the following cycling parameters (95C 45 s, 60C 30 s, 72C 45 s). 
Dissociation curves and agarose gels demonstrated a single PCR product in each case 
without primer dimmers. Gapdh was amplified using a TaqMan assay (Life Technologies) 
and default cycling parameters. Negative control reactions lacking RT yielded little or no 
Pfk or Gapdh signal, and relative expression levels were determined using the ΔΔCt method.
2.6 Metabolomics Determination by GC–MS Instrumentation
Cardiac tissue was flash frozen in a liquid nitrogen cooled biopress, a fraction of it weighed 
(~25–50 mg wet weight), then the finely cut up tissue quickly added to fresh pre-made 
buffer (50 % acetyl-nitrile, 50 % water, 0.3 % formic acid) at a standard concentration of 25 
mg/475 mcl buffer then fully homogenized on ice for 10–25 s and placed on dry ice/stored 
at −80C. The samples were “crash” deprotonized by methanol precipitation and spiked with 
D27-deuterated myristic acid (D27-C14:0) as an internal standard for retention-time locking 
and dried. The trimethylsilyl (TMS)-D27-C14:0 standard retention time (RT) was set at 
~16.727 min. Reactive carbonyls were stabilized at 50 °C with methoxyamine hydrochloride 
in dry pyridine. Metabolites were made volatile with TMS groups using N-methyl-N-
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(trimethylsilyl) trifluoroacetamide or MSTFA with catalytic trimethylchlorosilane at 50 °C. 
GC/MS methods generally follow those of Roessner et al. (2000), Fiehn et al. (2008), and 
Kind et al. (2009), and used a 6890 N GC connected to a 5975 Inert single-quadrupole MS 
(Agilent Technologies, Santa Clara, CA). The two wall-coated, open-tubular (WCOT) GC 
columns connected in series are both from J&W/Agilent (part 122–5512), DB5-MS, 15 
meters in length, 0.25 mm in diameter, with an 0.25-μm luminal film. Positive ions 
generated with conventional electron-ionization (EI) at 70 eV are scanned broadly from 600 
to 50 m/z in the detector throughout the 45 min cycle time.
Data were acquired using an MSD ChemStation (Agilent Technologies) by identifying 
metabolites on their mass fragmentation patterns and RT. Rawdata formatted files were 
exported for further analysis in Automatic Mass Spectral Deconvolution and Identification 
Software or AMDIS (freeware developed by Drs. Steve Stein, W. Gary Mallard, and their 
coworkers at National Institute of Standards and Technology or NIST (Mallard and Reed 
1997; Halket et al. 1999; Stein 1999). Deconvoluted spectra are annotated as metabolites, to 
the extent possible, using an orthogonal approach that incorporates both RT from GC and 
the fragmentation pattern observed in EI-MS. Peak annotation is based primarily on our own 
RT-locked spectral library of metabolites. The library is built upon the Fiehn GC/MS 
Metabolomics RTL Library (a gift from Agilent, part number G1676-90000; Kind et al. 
(2009), Golm Metabolome Library (courtesy of Dr. Joachim Kopka and coworkers at the 
Max Planck Institute of Molecular Plant Physiology, Golm, Germany (Kopka 2005) the 
Wiley 9th-NIST 2011 commercial library (Agilent G1730-64000), and other spectral 
libraries. Once annotation was complete, a cross-tabulated spreadsheet was created, listing 
the integrated peak area for each metabolite versus sample identity. This was accomplished 
using a custom Visual Basic program in Microsoft Excel that grouped peaks across samples 
based on identical metabolite annotation and RT proximity. Peak alignment across samples 
was further confirmed using SpectConnect (Styczynski et al. 2007) to assess similarity in 
spectral fragmentation patterns, and by manual curation. The raw, transformed, and sorted 
data used for each of the three comparisons in the metabolomic analyses (next) can be found 
in Supplemental Table 1.
2.7 Metabolomic Analyses
Metaboanalyst (v2.0) run on the statistical package R (v2.14.0) used metabolite peaks areas 
(as representative of concentration) (Xia et al. 2009, 2012). These data were first analyzed 
by an unsupervised principal component analysis (PCA), which identified the presence of 
the Brg1/Brm double mutant as the principal source of variance. To sharpen the separation 
between our three groups, data were next analyzed using a partial least squares discriminant 
analysis (PLS-DA) to further determine which metabolites were responsible for separating 
these two groups. The specific metabolites contributing most significantly to the differences 
identified by PLS-DA between Brg1/Brm double mutant and control group hearts were 
determined using the variable importance in projection (VIP) analysis in the metaboanalyst 
environment. The metabolites that best differentiated the groups were then individually 
tested using the Student’s t test (Microsoft Excel 2011, Seattle, WA). The t test significant 
metabolites were matched to metabolomics pathways using the Pathway Analysis feature in 
Metaboanalyst 2.0. Heat maps of the metabolite data (individual and grouped) were 
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generated using the GENE-E software (http://www.broadinstitute.org/cancer/software/
GENE-E/index.html).
3 Results and Discussion
To determine whether there is functional compensation of Brg1 and Brm in adult 
cardiomyocytes, we generated Brg1 floxed/floxed mice carrying the αMHC-Cre-ERT 
transgene on a Brm-deficient background. To induce the Brg1 conditional mutation in 
cardiomyocytes, these mice were treated with oral tamoxifen by providing it in their chow 
for 7 days (Brg1/Brm double mutant). As a control, the same Brg1floxed/floxed; αMHC-Cre-
ERT+/0; Brm−/− mice did not receive any tamoxifen treatment (Control Group 1). This 
control group addressed the potential for transgene leakiness (i.e., tamoxifen-independent 
induction of the Brg1 mutation). As a second control, Brg1 floxed/floxed mice lacking the 
αMHC-Cre-ERT transgene on a Brm-deficient background (Brg1floxed/floxed; αMHC-Cre-
ERT0/0; Brm−/−) were treated with tamoxifen (Control Group 2). This control group 
addressed the potential for tamoxifen having off-target effects unrelated to the Cre-ERT 
transgene. Rapid onset of cardiac dysfunction (Fig. 1a; Table 1), evidenced by significant 
decreases in Brg1-Brm DM mice ejection fraction % (42.0 vs. 88.6 % in Control Groups 1 & 
2) and factional shortening % (21.3 vs. 57.3 % in Control Groups 1 & 2), led to the rapid 
onset of death (Fig. 1b) in Brg1/Brm double mutants, but not in either control group. 
Kaplan–Meier analysis illustrates the first deaths occurring at day 13, with all other 
Brg1/Brm double mutants dying by day 22 relative to the first day of tamoxifen-fortified 
chow (which was provided on days 1–7). No histological changes were detected in the 
Brg1/Brm double mutant hearts, but increases in LV Mass/BW were identified (6.2 ± 0.3 
mg/g vs. 4.2 ± 0.1 mg/g Brm−/− flx/flx Brg1 Tg+ given 7 days of Tamoxifen at 1 day 
premortem, average day 11.6 ± 1.5 days, N = 27 and 30, respectively, *p<0.05 by Student’s 
t test). The cardiac phenotype of double mutants included changes in mitochondrial 
dynamics and accumulation storage vacuoles based on our analysis of H&E-stained sections 
(Fig. 1c) and TEM (Fig. 1d). Therefore, we considered the possible role of SWI/SNF 
complexes in regulating cardiomyocyte metabolism. To detect proximal events leading to 
heart failure and death, we investigated changes in the metabolomic profiles of Brg1/Brm 
double-mutant mice on day 9, which was 2 days after tamoxifen treatment ended. Day 9 was 
also a point prior to any signs of adverse health and 4 days before any of the mice were 
found to die (Fig. 1b).
Compared to the group 1 sibling-matched controls, quantitative non-targeted metabolomics 
profiling identified distinct differences in the Brm/Brg1 double mutant hearts by PCA and 
PLS-DA analysis (Fig. 2a, b, respectively). In both analyses, the principal component 1 
accounted for 55 % of the differences between the two groups. Further analysis of the top 15 
metabolites using a VIP that differentiated the Brg1/Brm double-mutant hearts from the 
group 1 controls include phosphoric acid, α-monostearin, urea, glutamic acid, and lactic acid 
(Fig. 2c).
Compared to the group 2 sibling-matched controls, metabolomics non-targeted profiling 
identified distinct differences in Brg1/Brm double-mutant mice by PCA and PLS-DA 
analysis (Fig. 2d, e). Between 47.8 and 51.6 % of the differences between these groups 
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accounted for the variability described by principal component 1. Like the analysis of the 
Brg1/Brm double-mutant mice compared to the group 1 controls, the top 15 metabolites 
using a VIP analysis to differentiate Brg1/Brm double-mutant mice from group 2 controls 
included phosphoric acid, glutamic acid, 2-aminoadipic acid, myoinositol, creatinine, and 
taurine (Fig. 2f). Since these two analyses differed in ways that may have been due to the 
presence of tamoxifen treatment, we chose next to combine the two control groups (Groups 
1 and 2) and compared them to the Brg1/Brm double-mutant mice (Fig. 2g, h, i). By PCA 
analysis, principal component 1 accounted for 55.5 % of the variability between the two 
groups and by PLS-DA, principal components 1–3 accounted for 12.4, 39.6, and 20.1 %, 
respectively and separated out the two groups distinctly (Fig. 2h). VIP analysis identified 
creatinine, taurine, 2-aminoadipic acid, glucose-6-phosphate, α-monostearin, and linoleic 
acid as the top significant hits (Fig. 2i). Comparison of the top 15 VIP hits between the three 
analyses performed, creatinine, linoleic acid, and glucose-6-phosphate were consistently 
found and represent differences not dependent upon the types of controls used (Table 2, in 
bold).
The comparisons of Brg1/Brm double-mutant mice to Group 1, Group 2, and Groups 1 & 2 
were performed to demonstrate the need for multiple controls (i.e. how tamoxifen and 
genetic backgrounds influence cardiac metabolites individually). The consistent differences 
Brg1/Brm double-mutant mice have independent of their genotype and strain (Group 1) and 
Tamoxifen (Group 2) was most dependably determined when Groups 1 and 2 were 
combined (Fig. 2g–i). Differences in Groups 1 and Group 2 were identified, as expected due 
to the tamoxifen treatment. For example, differences were detected by PCA, PLS-DA, and t 
test analysis (Supplemental Fig. 1). The differences between Groups 1 and 2 are limited, due 
to the low number (N = 3) of biological replicates run in these subgroups. The comparison 
of Brg1/Brm double-mutant samples to the combined Groups 1 and 2 allowed identification 
of metabolic signatures that are independent of the Brg1/Brm-null phenotype.
The studies presented here have limitations that should be acknowledged. While the GC–MS 
method applied here allows global definitions of metabolism, it is not expected that all of the 
possible metabolites present would be identified. Identification of metabolites is also limited 
to molecules with unambiguous chemical annotation in established metabolite libraries; the 
exploratory nature of non-targeted metabolomics methodologies has the limitation of being 
semi-quantitative based on the their RTs (vs. an internal standard) and mass fragmentation 
patterns. The use of non-targeted metabolomics in the present study was to determine the 
underlying metabolic changes, to allow insight into the systems level changes. However, 
specific mechanisms identified need further validation to make specific conclusions. 
Additionally, a second limitation is the limited number of experimental replicates per group 
(6–8/group, Fig. 2g–i). Previous studies have noted an increasing chance of false-positive 
findings with reduced statistical power when replicates are limited, a common problem also 
associated with high throughput technologies in general; it is also possible that relevant 
markers have been similarly dismissed (Drogan et al. 2014; Floegel et al. 2013). For these 
reasons, the use of an internal control for each chemical class of specific metabolites in 
question should be used to validate these results. Based on this context, we focus our 
Banerjee et al. Page 8













discussion here on the metabolomics signatures and our limited validation of specific 
enzyme effects.
The unsupervised heat maps illustrating the differences in metabolite quantities for each of 
the three individual analyses, identified metabolites that were different from the controls by 
5.3 to 0.35 fold (Fig. 3a, b, c). When individual VIP significant metabolites were identified 
in the three analyses, serine, linoleic acid, oleic acid, and taurine were >2.0 fold and 
fructose-6-phosphate, glucose-6-phosphate, creatinine, myoinositol were decreased <0.8 
fold and compared to controls (Fig. 3d). We next took the VIP significant metabolites that 
were also t test significant in the three comparisons (control groupings) and performed a 
pathway enrichment analysis (Table 3). All three comparisons consistently identified oleic 
acid and linoleic acid as significant, with the combined controls additionally identifying 
fructose-6-phosphate, creatinine, and alanine as significant.
The significant metabolic pathways that were identified included (1) biosynthesis of 
unsaturated fatty acids and (2) linoleic acid metabolism; (Table 3, right column). In the 
context of VIP significant metabolites (Fig. 3d), increased linoleic acid may broadly involve 
arachidonic acid pathways (Fig. 4a). Decreased glucose-6-phophate and fructose-6-
phosphate (<0.5 fold) and downstream myoinositol (decreased <0.8 fold) (Fig. 3d), illustrate 
multiple points in which glucose metabolism is affected in amino sugar and nucleotide sugar 
metabolism (Fig. 4b). Similarly, evidence of alterations in alanine metabolism (increases in 
threonine, alanine, and serine metabolites, Fig. 3d) represents potential increases in the 
ability to create pyruvate through these pathways (Supplemental Fig. 2a). Finally, decreased 
creatinine and increases in urea (Fig. 3d) illustrate where reducing cardiomyocyte Brg1/Brm 
expression affects creatine and creatinine metabolism in vivo (Supplemental Fig. 2b). The 
mechanistic relevance of these findings in this mouse model is not clear, but the importance 
of each of these metabolites in cardiac (patho)physiology may offer insights for future 
investigations.
Both linoleic acid and oleic acid are polyunsaturated fatty acids involved in critical cellular 
processes in the heart. Recent metabolomics studies of angiotensin II (Ang II)-induced 
cardiac hypertrophy in Sprague–Dawley and double transgenic rats harboring human renin 
and angiotensinogen genes challenged with Ang II blockade found that the double 
transgenic rats had the greatest differences in the use of fatty acids, having decreased oleic 
and linoleic acids (Mervaala et al. 2010). Morphological changes suggesting an increase in 
mitochondrial fusion and altered cardiac expression of the redox-sensitive and 
cardioprotective metabolic sensor sirtuin 1 was increased in the double transgenic rats 
(Mervaala et al. 2010). The metabolomics changes and mitochondrial biogenesis induced by 
Ang II was inhibited by valsartan, illustrating the specificity of the Ang II in the regulation 
of mitochondrial biogenesis and alterations in metabolomics (Mervaala et al. 2010).
Increased oleic and linoleic acid in the Brg1/Brm double- mutant hearts may be linked 
directly or indirectly to the role of the SWI/SNF complex in the regulation of fatty acid 
utilization. The SWI/SNF complex has been implicated in regulating fatty acid oxidation by 
its interactions with peroxisome proliferator activated receptors (PPARs). The PPAR nuclear 
receptors, in coordination with RXRα and co-activators such as PGC-1α, act as transcription 
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factors for genes encoding proteins responsible for fatty acid uptake and oxidation. BRG1 
and BRM-catalyzed SWI/SNF complexes functionally interact with a variety of nuclear 
hormone receptors (transcription factors) including the PPAR isoforms (Trotter and Archer 
2007; Viswakarma et al. 2010). For example, BAF180, which binds the PPARγ-RXRα 
complex, contains six bromodomains that bind selectively to acetylated histone tails 
required for targeting the co-regulator complex to chromatin (Lemon et al. 2001). BRG1 and 
BRM themselves have been identified in the PPAR-γ promoter, and the SWI/SNF complex 
itself is critical to the transcriptional regulation of PPAR-γ during the formation of 
preinitiation complexes (Salma et al. 2004). Other BAFs are critical for PPAR activity, with 
BAF60c interacting with the ligand-binding domain of PPAR-γ and BAF60c reported to 
bind the C-terminal PPAR-γ domain in a ligand-dependent manner (Debril et al. 2004). 
BAF60a is a partner of the PPAR co-activator PGC-1α (Li et al. 2008) and is involved in 
regulating lipid metabolism by its crosstalk with PPARβ/δ (Gatfield et al. 2009; Wang et al. 
1996). The changes in fatty acids used as energy substrates, including oleic acid in the 
present study, may reflect alterations in fatty acid utilization in the absence of SWI/SNF 
support of PPAR activity. It is also possible that SWI/SNF alters linoleic acid by its 
alterations in the mitochondria. Specifically, alterations in the physicochemical properties of 
membranes, including cardiolipins, could contribute to the cardiac phenotypes reported here 
(Sparagna and Lesnefsky 2009). Recent studies have identified that linoneic acid preserves 
mitochondrial cardiolipin found in the inner membrane and attenuates mitochondrial 
dysfunction in heart failure (He and Han 2014; Mulligan et al. 2012). In the present study, 
the increases in linoleic acid may reflect this response to protect against heart failure. Direct 
evidence of altered PPAR activity or mitochondrial cardiolipin is beyond the scope of the 
present study but merits consideration in the underlying mechanisms that SWI/SNF plays in 
preserving adult cardiomyocyte function.
Effects on glucose storage as glycogen may also be seen in the Brg1/Brm double-mutant 
hearts. Alterations in cardiac glucose-6-phosphate (G-6-P) and fructose-6-phosphate (F-6-P) 
has been reported in previous metabolomics studies. Specifically, increased levels of G-6-P 
and F-6-P have been seen when phosphofructokinase (PFK) activity was experimentally 
inhibited (McDonald et al. 2014). By mediating the flow of substrate from F-6-P to 
Fructose-1,6 BisP, PFK initiates start of glycolysis and downstream utilization of glucose 
ultimately for generating energy. Mice lacking muscle PFK (PFKM−/−) exhibit cardiac 
hypertrophy with age, impaired oxidative metabolism, muscle fiber necrosis, and impaired 
exercise tolerance (Garcia et al. 2009). Similarly, mutations in muscle PFK are found in 
patients resulting in glycogen storage diseases (Raben and Sherman 1995), characterized by 
muscle weakness, exercise intolerance, and the inability to utilize carbohydrates for energy 
production well (Nakajima et al. 2002). Increases in threonine, serine, and alanine in alanine 
metabolism and decreases in cardiac creatinine (Supplemental Fig. 2a, b, respectively) have 
not previously been reported in metabolomics studies or linked to the SWI/SNF complex 
previously and may represent mechanistic links unique to the cardiomyocyte or the unique 
redundant role of Brg1/Brm in the maintenance of the adult cardiomyocyte in vivo.
Mice lacking liver SNF5/BAF47 die due to post-natal hypoglycemia linked to impaired 
glycogen storage due to transcriptional down regulation of phosphofructose kinase fructose 
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biphosphatase (PFKFB1), illustrating the critical role of the SWI/SNF complex in glucose 
metabolism(Gresh et al. 2005). By specifically inhibiting PFK activity, increases in G-6-P 
and F-6-P levels may have been identified as in the present study, where we impaired the 
SWI/SNF complex (by inducing cardiomyocyte-specific loss of Brg1/Brm). In contrast to 
the liver SNF5/BAF47 study, we did not observe a significant difference in PFKFB1 mRNA 
levels (Supplemental Fig. 3). This finding is not necessarily surprising because the SNF5/
BAF47 and BRG1 subunits are known to regulate different target genes and to have 
different effects in tumor suppression.
4 Concluding Remarks
Previously, the BRG1 and BRM catalytic subunits of SWI/SNF complexes were shown to 
have a functionally redundant role in maintaining the viability in VECs, resulting in primary 
defects in the heart, including cardiac dissection, cardiac necrosis, and death (Willis et al. 
2012). In the present study, we took a non-targeted approach to metabolomically analyze the 
effects of inducing the simultaneous loss of Brg1 and Brm in adult cardiomyocytes at an 
early time point before the lethal effects were seen in vivo. Since the Brg1/Brm double-
mutant model had both a genetic component and a tamoxifen feeding component, two types 
of controls were used and analyzed separately and together to identify significant differences 
in creatinine, linoleic acid, glucose-6-phosphate, oleic acid, and serine (Table 2). The 
increased oleic and linoleic acid in the Brg1/Brm double-mutant hearts may be linked to the 
role of the SWI/SNF complex in the regulation of PPARs, instrumental to the mainly fatty 
acid oxidation the heart uses as a primary energy source (Neubauer 2007). While the link 
between BRG1 and BRM regulation of PPARs is limited, impairment of the SWI/SNF 
complex leads to altered PPAR activity in non-cardiomyocyte cells has been previously 
identified (Debril et al. 2004; Gatfield et al. 2009; Lemon et al. 2001; Salma et al. 2004; 
Wang et al. 1996) and may offer clues to novel ways in which BRG1 and BRM redundantly 
regulate cardiomyocyte fatty acid oxidation for future studies. Similarly, the decreases in 
cardiac G-6-P and F-6-P (Fig. 2) illustrate a dysregulation in downstream glycolysis and 
glycogen formation, and may reflect more complex alterations of enzymes both up and 
downstream (Garcia et al. 2009; Nakajima et al. 2002; Raben and Sherman 1995).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Ang II Angiotensin II
BAFs BRG1- or BRM-associated factors
Brg1 Brahma-related gene 1
Brm Brahma
Flx LoxP-flanked DNA polymerase gene
F-6-P Fructose-6-phosphate
G-6-P Glucose-6-phosphate
α-MHC-Cre-ERT Cre recombinase fused to a mutated ligand-binding domain of 
human estrogen receptor
RXRα Retinoid X receptor alpha
PPAR Peroxisome proliferator activated receptor
PGC-1α PPAR-gamma coactivator 1-alpha
VECs Vascular endothelial cells
VIP Variable importance in projection
References
Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to 
diabetes research: Moving from information to knowledge. Diabetes. 2009; 58:2429–2443.10.2337/
db09-0580 [PubMed: 19875619] 
Bevilacqua A, Willis MS, Bultman SJ. SWI/SNF chromatin-remodeling complexes in cardiovascular 
development and disease. Cardiovascular Pathology. 201310.1016/j.carpath.2013.09.003
Bultman S, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian 
SWI/SNF complexes. Molecular Cell. 2000; 6:1287–1295. [PubMed: 11163203] 
Carley AN, Taegtmeyer H, Lewandowski ED. Matrix revisited: Mechanisms linking energy substrate 
metabolism to the function of the heart. Circulation Research. 2014; 114:717–729.10.1161/
CIRCRESAHA.114.301863 [PubMed: 24526677] 
Chang CP, Bruneau BG. Epigenetics and cardiovascular development. Annual Review of Physiology. 
2012; 74:41–68.10.1146/annurev-physiol-020911-153242
Curtis CD, Davis RB, Ingram KG, Griffin CT. Chromatin-remodeling complex specificity and 
embryonic vascular development. Cellular and Molecular Life Sciences. 201210.1007/
s00018-012-1023-4
Debril MB, Gelman L, Fayard E, Annicotte JS, Rocchi S, Auwerx J. Transcription factors and nuclear 
receptors interact with the SWI/SNF complex through the BAF60c subunit. Journal of Biological 
Chemistry. 2004; 279:16677–16686.10.1074/jbc.M312288200 [PubMed: 14701856] 
Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: Implications beyond ATP 
production. Circulation Research. 2013; 113:709–724.10.1161/CIRCRESAHA.113.300376 
[PubMed: 23989714] 
Drogan D, et al. Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes 
mellitus in a prospective, nested case-control study. Clinical Chemistry. 201410.1373/clinchem.
2014.228965
Fiehn O, et al. Quality control for plant metabolomics: Reporting MSI-compliant studies. Plant 
Journal. 2008; 53:691–704.10.1111/j.1365-313X.2007.03387.x [PubMed: 18269577] 
Banerjee et al. Page 12













Files DC, et al. A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle 
wasting. American Journal of Respiratory and Critical Care Medicine. 2012; 185:825–
834.10.1164/rccm.201106-1150OC [PubMed: 22312013] 
Floegel A, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a 
targeted metabolomic approach. Diabetes. 2013; 62:639–648.10.2337/db12-0495 [PubMed: 
23043162] 
Frazier DM, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 
1997–2005. Journal of Inherited Metabolic Disease. 2006; 29:76–85.10.1007/s10545-006-0228-9 
[PubMed: 16601872] 
Garcia M, et al. Phosphofructo-1-kinase deficiency leads to a severe cardiac and hematological 
disorder in addition to skeletal muscle glycogenosis. PLOS Genetics. 2009; 5:e1000615.10.1371/
journal.pgen.1000615 [PubMed: 19696889] 
Gatfield D, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes and 
Development. 2009; 23:1313–1326.10.1101/gad.1781009 [PubMed: 19487572] 
Gresh L, et al. The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte 
differentiation. EMBO Journal. 2005; 24:3313–3324.10.1038/sj.emboj.7600802 [PubMed: 
16138077] 
Griffin CT, Brennan J, Magnuson T. The chromatin-remodeling enzyme BRG1 plays an essential role 
in primitive erythropoiesis and vascular development. Development. 2008; 135:493–500.10.1242/
dev.010090 [PubMed: 18094026] 
Griffin CT, Curtis CD, Davis RB, Muthukumar V, Magnuson T. The chromatin-remodeling enzyme 
BRG1 modulates vascular Wnt signaling at two levels. Proceedings of the National Academy of 
Sciences USA. 2011; 108:2282–2287.10.1073/pnas.1013751108
Halket JM, Przyborowska A, Stein SE, Mallard WG, Down S, Chalmers RA. Deconvolution gas 
chromatography/mass spectrometry of urinary organic acids–potential for pattern recognition and 
automated identification of metabolic disorders. Rapid Communications in Mass Spectrometry. 
1999; 13:279–284.10.1002/(SICI)1097-0231(19990228) [PubMed: 10097403] 
Han P, Hang CT, Yang J, Chang CP. Chromatin remodeling in cardiovascular development and 
physiology. Circulation Research. 2011; 108:378–396.10.1161/CIRCRESAHA.110.224287 
[PubMed: 21293009] 
Hang CT, et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. 
Nature. 2010; 466:62–67.10.1038/nature09130 [PubMed: 20596014] 
He Q, Han X. Cardiolipin remodeling in diabetic heart. Chemistry and Physics of Lipids. 2014; 
179:75–81.10.1016/j.chemphyslip.2013.10.007 [PubMed: 24189589] 
Kadoch C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies 
extensive roles in human malignancy. Nature Genetics. 2013; 45:592–601.10.1038/ng.2628 
[PubMed: 23644491] 
Kind T, et al. FiehnLib: Mass spectral and retention index libraries for metabolomics based on 
quadrupole and time-of-flight gas chromatography/mass spectrometry. Analytical Chemistry. 
2009; 81:10038–10048.10.1021/ac9019522 [PubMed: 19928838] 
Koitabashi N, et al. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-
induced MerCreMer gene deletion models. Circulation Research. 2009; 105:12–15.10.1161/
CIRCRESAHA.109.198416 [PubMed: 19520971] 
Kolwicz SC Jr, Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, 
and survival of cardiomyocytes. Circulation Research. 2013; 113:603–616.10.1161/
CIRCRESAHA.113.302095 [PubMed: 23948585] 
Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmueller E, Doermann P, Weckwerth 
W, Gibon Y, Stitt M, Willmitzer L, Fernie AR, Steinhauser D. GMD@CSB.DB: The Golm 
Metabolome Database. Bioinformatics. 2005; 21(8):1635–1638.10.1093/bioinformatics/bti236 
[PubMed: 15613389] 
Kosho T, Kuniba H, Tanikawa Y, Hashimoto Y, Sakurai H. Natural history and parental experience of 
children with trisomy 18 based on a questionnaire given to a Japanese trisomy 18 parental support 
group. American Journal of Medical Genetics A. 2013a; 161A:1531–1542.10.1002/ajmg.a.35990
Banerjee et al. Page 13













Kosho T, et al. Clinical correlations of mutations affecting six components of the SWI/SNF complex: 
Detailed description of 21 patients and a review of the literature. American Journal of Medical 
Genetics A. 2013b; 161:1221–1237.10.1002/ajmg.a.35933
Lei I, Gao X, Sham MH, Wang Z. SWI/SNF protein component BAF250a regulates cardiac progenitor 
cell differentiation by modulating chromatin accessibility during second heart field development. 
Journal of Biological Chemistry. 2012; 287:24255–24262.10.1074/jbc.M112.365080 [PubMed: 
22621927] 
Lemon B, Inouye C, King DS, Tjian R. Selectivity of chromatin-remodelling cofactors for ligand-
activated transcription. Nature. 2001; 414:924–928.10.1038/414924a [PubMed: 11780067] 
Li S, et al. Genome-wide coactivation analysis of PGC-1alpha identifies BAF60a as a regulator of 
hepatic lipid metabolism. Cell Metabolism. 2008; 8:105–117.10.1016/j.cmet.2008.06.013 
[PubMed: 18680712] 
Lickert H, et al. Baf60c is essential for function of BAF chromatin remodelling complexes in heart 
development. Nature. 2004; 432:107–112.10.1038/nature03071 [PubMed: 15525990] 
Mallard, WG.; Reed, J. Automated mass spectral deconvolution and identification system: AMDIS 
user guide. Gaithersburg: National Institute of Standards and Technology, US Department of 
Commerce; 1997. p. ivp. 58
McDonald TS, Tan KN, Hodson MP, Borges K. Alterations of hippocampal glucose metabolism by 
even versus uneven medium chain triglycerides. Journal of Cerebral Blood Flow and Metabolism. 
2014; 34:153–160.10.1038/jcbfm.2013.184 [PubMed: 24169853] 
Mervaala E, et al. Metabolomics in angiotensin II-induced cardiac hypertrophy. Hypertension. 2010; 
55:508–515.10.1161/HYPERTENSIONAHA.109.145490 [PubMed: 20065148] 
Mulligan CM, et al. Dietary linoleate preserves cardiolipin and attenuates mitochondrial dysfunction in 
the failing rat heart. Cardiovascular Research. 2012; 94:460–468.10.1093/cvr/cvs118 [PubMed: 
22411972] 
Nakajima H, Raben N, Hamaguchi T, Yamasaki T. Phosphofructokinase deficiency; past, present and 
future. Current Molecular Medicine. 2002; 2:197–212. [PubMed: 11949936] 
Nelson TJ, Balza R Jr, Xiao Q, Misra RP. SRF-dependent gene expression in isolated cardiomyocytes: 
Regulation of genes involved in cardiac hypertrophy. Journal of Molecular and Cellular 
Cardiology. 2005; 39:479–489.10.1016/j.yjmcc.2005.05.004 [PubMed: 15950986] 
Neubauer S. The failing heart–an engine out of fuel. New England Journal of Medicine. 2007; 
356:1140–1151.10.1056/NEJMra063052 [PubMed: 17360992] 
Oakley RH, et al. Essential role of stress hormone signaling in cardiomyocytes for the prevention of 
heart disease. Proceedings of the National Academy of Sciences USA. 2013; 110:17035–
17040.10.1073/pnas.1302546110
Raben N, Sherman JB. Mutations in muscle phosphofructokinase gene. Human Mutation. 1995; 6:1–
6.10.1002/humu.1380060102 [PubMed: 7550225] 
Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. Altered control of cellular 
proliferation in the absence of mammalian brahma (SNF2alpha). EMBO Journal. 1998; 17:6979–
6991.10.1093/emboj/17.23.6979 [PubMed: 9843504] 
Roessner U, Wagner C, Kopka J, Trethewey RN, Willmitzer L. Technical advance: Simultaneous 
analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant J. 2000; 
23:131–142. [PubMed: 10929108] 
Ronan JL, Wu W, Crabtree GR. From neural development to cognition: Unexpected roles for 
chromatin. Nature Reviews Genetics. 2013; 14:347–359.10.1038/nrg3413
Salma N, Xiao H, Mueller E, Imbalzano AN. Temporal recruitment of transcription factors and 
SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome 
proliferator-activated receptor gamma nuclear hormone receptor. Molecular and Cellular Biology. 
2004; 24:4651–4663.10.1128/MCB.24.11.4651-4663.2004 [PubMed: 15143161] 
Santen GW, et al. Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-
Siris syndrome. Nature Genetics. 2012; 44:379–380.10.1038/ng.2217 [PubMed: 22426309] 
Sohal DS, et al. Temporally regulated and tissue-specific gene manipulations in the adult and 
embryonic heart using a tamoxifen-inducible Cre protein. Circulation Research. 2001; 89:20–25. 
[PubMed: 11440973] 
Banerjee et al. Page 14













Sparagna GC, Lesnefsky EJ. Cardiolipin remodeling in the heart. Journal of Cardiovascular 
Pharmacology. 2009; 53:290–301.10.1097/FJC.0b013e31819b5461 [PubMed: 19276988] 
Stankunas K, et al. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for 
myocardial morphogenesis. Developmental Cell. 2008; 14:298–311.10.1016/j.devcel.2007.11.018 
[PubMed: 18267097] 
Stein SE. An integrated method for spectrum extraction and compound identification from GC/MS 
data. Journal of the American Society for Mass Spectrometry. 1999; 10(8):770–781.
Styczynski MP, Moxley JF, Tong LV, Walther JL, Jensen KL, Stephanopoulos GN. Systematic 
identification of conserved metabolites in GC/MS data for metabolomics and biomarker discovery. 
Analytical Chemistry. 2007; 79:966–973.10.1021/ac0614846 [PubMed: 17263323] 
Sumi-Ichinose C, Ichinose H, Metzger D, Chambon P. SNF2beta-BRG1 is essential for the viability of 
F9 murine embryonal carcinoma cells. Molecular and Cellular Biology. 1997; 17:5976–5986. 
[PubMed: 9315656] 
Takeuchi JK, Bruneau BG. Directed transdifferentiation of mouse mesoderm to heart tissue by defined 
factors. Nature. 2009; 459:708–711.10.1038/nature08039 [PubMed: 19396158] 
Takeuchi JK, et al. Chromatin remodelling complex dosage modulates transcription factor function in 
heart development. Nature Communications. 2011; 2:187.10.1038/ncomms1187
Trotter KW, Archer TK. Nuclear receptors and chromatin remodeling machinery. Molecular and 
Cellular Endocrinology. 2007; 265–266:162–167.10.1016/j.mce.2006.12.015
Tsurusaki Y, et al. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris 
syndrome. Nature Genetics. 2012; 44:376–378.10.1038/ng.2219 [PubMed: 22426308] 
Van Houdt JK, et al. Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser 
syndrome. Nature Genetics. 2012; 44(445–9):S1.10.1038/ng.1105
Viswakarma N, et al. Coactivators in PPAR-regulated gene expression. PPAR Research. 
201010.1155/2010/250126
Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR. Diversity and specialization of mammalian 
SWI/SNF complexes. Genes and Development. 1996; 10:2117–2130. [PubMed: 8804307] 
Wang Z, et al. Polybromo protein BAF180 functions in mammalian cardiac chamber maturation. 
Genes and Development. 2004; 18:3106–3116.10.1101/gad.1238104 [PubMed: 15601824] 
Willis MS, et al. Muscle ring finger 1 mediates cardiac atrophy in vivo. American Journal of 
Physiology Heart and Circulatory Physiology. 2009a; 296:H997–H1006.10.1152/ajpheart.
00660.2008 [PubMed: 19168726] 
Willis MS, et al. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. 
Circulation Research. 2009b; 105:80–88.10.1161/CIRCRESAHA.109.194928 [PubMed: 
19498199] 
Willis MS, et al. Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular 
endothelial cells in the adult heart. Circulation Research. 2012; 111:e111–e122.10.1161/
CIRCRESAHA.112.265587 [PubMed: 22740088] 
Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell. 2009; 
136:200–206.10.1016/j.cell.2009.01.009 [PubMed: 19167321] 
Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0–a comprehensive 
server for metabolomic data analysis. Nucleic Acids Research. 2012; 40:W127–
W133.10.1093/nar/gks374 [PubMed: 22553367] 
Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: A web server for metabolomic data 
analysis and interpretation. Nucleic Acids Research. 2009; 37:W652–W660.10.1093/nar/gkp356 
[PubMed: 19429898] 
Banerjee et al. Page 15














The phenotype of Brg1/Brm double-mutant mice. a Kaplan–Meier survival curve of mice 
following the administration of tamoxifen (+TAM) on days 1 through 7. b Longitudinal 
echo time course of an example control group 2 (Brg1floxed/floxed; αMHC-Cre-ERT0/0(no 
transgene); Brm−/− mice plus tamoxifen treatment) and a Brg1/Brm double mutant 
(Brg1floxed/floxed; αMHC-Cre-ERT+/0; Brm−/− mice plus tamoxifen treatment) illustrating the 
rapid decline in systolic function and dilation upon deletion of Brg1 with tamoxifen 
induction (via chow). c Representative H&E-stained heart sections from control (left) and 
double mutant (right) mice at ×200 magnification. d Representative transmission electron 
micrographs of cardiomyocytes from control (left) and double mutant (right) mice at ×5000 
magnification. Illustrating accumulation of vacuoles in the mitochondria interspersed in the 
sarcomere (white arrows) that were found adjacent to fragmented mitochondria
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The metabolomic profiles of Brg1/Brm double-mutant hearts are significantly different from 
control hearts prepared and analyzed in parallel. Principal components analysis (PCA) 
illustrating the unsupervised relationship between Brg1/Brm double-mutant hearts 
(Brg1floxed/floxed; αMHC-Cre-ERT+/0; Brm−/− mice plus tamoxifen treatment) compared to a 
Control Group 1 (Brg1floxed/floxed; αMHC-Cre-ERT+/0; Brm−/− minus tamoxifen treatment) 
d Control Group 2 (Brg1floxed/floxed; αMHC-Cre-ERT0/0(no transgene); Brm−/− mice plus 
tamoxifen treatment), and g Combined Control Groups 1 & 2 hearts. Partial least squares 
discriminant analysis (PLS-DA) score visualizes supervised (assigned group) clustering of 
Brg1/Brm double-mutant heart metabolomics compared to b Control Group 1 e Control 
Group 2, and h Control Groups 1 & 2. Data points that are closer together indicate higher 
degree of similarity than data points that are further apart. PLS-DA score plots for Brg1/Brm 
double-mutant heart metabolites (red) compared to metabolites identified in control hearts 
(green). Each point represents the combined metabolite profile in an individual mouse. 
Variable importance in projection (VIP) plot of VIP statistical analysis identifying the top 15 
metabolites contributing to the differences between the Brg1/Brm double mutant and c 
Control Group 1 f Control Group 2, and i Control Groups 1 & 2 hearts (relative 
concentration to the right of the figure). N = 8 (Brg1/Brm double-mutant hearts), N = 3 
(Control Group 1), N = 3 (Control Group 2), N = 6 (Control Groups 1 & 2) hearts per group 
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analyzed. Each point represents an individual mouse heart run in parallel with the other 
samples (Color figure online)
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Unsupervised heat maps of all identified metabolites and their associated fold changes in 
Brg1/Brm double-mutant hearts compared to a Control Group 1 (Brg1floxed/floxed; αMHC-
Cre-ERT+/0; Brm−/− minus tamoxifen treatment), b Control Group 2 (Brg1floxed/floxed; 
αMHC-Cre-ERT0/0(no transgene); Brm−/− mice plus tamoxifen treatment), and c Combined 
Groups 1 & 2 controls. d Identification of the VIP significant metabolites (p<0.05). N = 8 
(Brg1/Brm double mutant hearts), N = 3 (Control Group 1), N = 3 (Control Group 2), N = 6 
(Control Groups 1 & 2) hearts per group analyzed
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Metabolic pathways related to cardiac Brg1/Brm double-mutant activity in vivo determined 
by non-targeted metabolomics analysis of ventricular cardiac tissue (see Table 3 for analytic 
details). Metabolites identified by VIP and t test significance are shown in red in the context 
of generalized pathways analysis (identified by metaboanalyst). a Biosynthesis of 
unsaturated fatty acids and fatty acid biosynthesis/linoleic acid metabolism; b Amino sugar 
and nucleotide sugar metabolism (adapted from http://www.genome.jp/kegg-bin/
show_pathway?map00520+C00031) (Color figure online)
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Table 2
VIP significant metabolites in Brm/Brg1 double mutant mice (Flx/Flx, Cre Tg+, +tamoxifen) 12 days after 
feeding initiated (7 days total, Groups 1 and 3 only). Brm/Brg1 double mutant
Control Group 1 (Flx/Flx, No Brg1 Tg, 
Chow+tamoxifen) versus Brm/Brg1 double 
mutant (VIP Rank)
Control Group 2 (Flx/Flx, Brg1 Tg+, Chow 
diet − no tamoxifen) versus Brm/Brg1 
double mutant (VIP Rank)
Control Groups 1 & 2 versus Brm/Brg1 
double mutant (Chow+tamoxifen) (VIP 
Rank)
Phosphoric Acid (1) Phosphoric acid (1) *
Alpha-monostearin (2) * Alpha-monostearin (5)
Urea (3) Urea (11) *
Glutamic acid (4) Glutamic acid (2) *
Lactic acid (5) Lactic acid (7) *
Cholesterol (6) * Cholesterol (12)
Stearic acid (7) * Stearic acid (15)
Creatinine (8) Creatinine (5) Creatinine (1)
Palmitic acid (9) * *
Linoleic acid (10) Linoleic acid (15) Linoleic acid (6)
Glucose-6-phosphate (11) Glucose-6-phosphate (9) Glucose-6-phosphate (4)
Fructose-6-phosphate (12) * Fructose-6-phosphate (9)
Alpha-monopalmitin (13) * Alpha-Monopalmitin (18)
Oleic acid (14) Oleic acid (16) Oleic acid (11)
Serine (15) Serine (14) Serine (7)
* 2-Aminoadipic acid (3) 2-Aminoadipic acid (3)
* Myoinositol (4) Myoinositol (10)
* Taurine (6) Taurine (2)
* Aldohexose (8) Aldohexose (8)
* Malic acid (10) Malic acid (14)
* Glycerol-1-phosphate (12) *
* Alanine (13) Alanine (13)
* * Adenosine (16)
* * Threonine (17)
The ranking (1–15) indicates the ranking given to the metabolites in their respective groups (Control Group 1, Control Group 2, Brg/Brm Double 
mutant Group 3)
Bold present in all three analyses
*
Indicates this metabolite was not found to be a VIP significant metabolite
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Table 3
VIP significant metabolites that were also t test significant (p < 0.05) in the three comparisons made in this 
study, along with the related matched pathways from pathway enrichment analysis
Comparison Metabolite (p value) Pathway (hits) p value
Control 1 versus Brg1/Brm double mutant Oleic acid (0.005) Biosynthesis of unsaturated fatty acids (2) 0.0009
Linoleic acid (0.008) Linoleic acid metabolism (1) 0.0080
Fatty acid biosynthesis (1) 0.0598a
Control 2 versus Brg1/Brm double mutant Alanine (0.005) Biosynthesis of unsaturated fatty acids (2) 0.0049
Oleic acid (0.010) Linoleic acid metabolism (1) 0.0168
Linoleic acid (0.0014) Ascorbate and aldarate metabolism (1) 0.0252
Myoinositol (0.0021) Galactose metabolism (1) 0.0715a
Inositol phosphate metabolism (1) 0.0768a
Fatty acid biosynthesis (1) 0.1161a
Control 1 & 2 versus Brg1/Brm double mutant Oleic acid (0.007) Biosynthesis of unsaturated fatty acids (2) 0.0081
Linoleic acid (0.010) Linoleic acid metabolism (1) 0.0210
Fructose-6-phosphate (0.016) Amino sugar and nucleotide sugar metabolism (1) 0.1241a
Creatinine (0.017) Fatty acid biosynthesis (1) 0.1429a
Alanine (0.033)
VIP significance was based on the analysis of Control group 1 (Flx/Flx, No Brg1 Tg, Chow+tamoxifen, N = 3), Control Group 2 (Flx/Flx, Brg1 Tg
+, Chow diet − no tamoxifen, N = 3), Control Groups 1 & 2 (Flx/Flx, No Brg1 Tg, Chow+tamoxifen AND Flx/Flx, Brg1 Tg+, Chow diet − no 
tamoxifen, N = 6), and Brg1/Brm Double Mutant (Chow+tamoxifen, N = 5) hearts
a
Not significant
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